Companies › Peel Therapeutics
1 active drug program in 3 registered trials: 3 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PEEL-224 | – | Phase 1 | Advanced Solid Tumor; Sarcoma; Refractory Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05329103 | PEEL-224 | Phase 1 | Advanced Solid Tumor | Oncology | Oct 2026 |
| NCT06709495 | PEEL-224 | Phase 1 | Sarcoma | Oncology | Nov 2028 |
| NCT06721689 | PEEL-224 | Phase 1 | Refractory Solid Tumors | Oncology | Apr 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.